Compare LEDS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | SNGX |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 12.3M |
| IPO Year | 2010 | 2006 |
| Metric | LEDS | SNGX |
|---|---|---|
| Price | $1.23 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.5K | ★ 112.9K |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,009,000.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.11 | $1.02 |
| 52 Week High | $3.37 | $6.23 |
| Indicator | LEDS | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 48.83 |
| Support Level | N/A | $1.19 |
| Resistance Level | $2.02 | $1.22 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 26.67 | 43.18 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).